News | July 29, 2024
Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
Subscribe To Our Newsletter & Stay Updated
